BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced several inducement grants of restricted stock units (RSUs) to new employees. The compensation committee approved RSU grants totaling 238,168 shares across 74 new employees between June and September 2025.
The RSU grants follow a consistent vesting schedule, with 25% of shares vesting after one year and the remaining shares vesting quarterly over the following three years, contingent on continued employment. These grants were made under the Company's Amended and Restated 2019 Inducement Equity Plan.
BridgeBio Pharma (Nasdaq: BBIO), una società biofarmaceutica specializzata nelle malattie genetiche, ha annunciato diversi incentivi in azioni vincolate (RSU) destinati a nuovi dipendenti. Il comitato per la remunerazione ha approvato concessioni di RSU per un totale di 238.168 azioni distribuite tra 74 nuovi dipendenti tra giugno e settembre 2025.
Le RSU seguono un piano di maturazione uniforme: il 25% delle azioni matura dopo un anno e il resto matura trimestralmente nei tre anni successivi, subordinatamente alla continuazione del rapporto di lavoro. Queste concessioni sono state effettuate nell'ambito del Piano Azionario di Induzione emendato e riformulato del 2019 della Società.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica centrada en enfermedades genéticas, ha anunciado varias concesiones de unidades restringidas de acciones (RSU) para nuevos empleados. El comité de compensación aprobó concesiones de RSU por un total de 238.168 acciones entre 74 nuevos empleados entre junio y septiembre de 2025.
Las RSU siguen un calendario de adquisición uniforme: el 25% de las acciones se adquiere tras un año y el resto se adquiere trimestralmente durante los tres años siguientes, condicionado a la continuidad en el empleo. Estas concesiones se realizaron bajo el Plan de Capital de Inducción enmendado y reformulado de 2019 de la Compañía.
BridgeBio Pharma (Nasdaq: BBIO)는 유전 질환에 주력하는 바이오제약사로, 신입 직원들에게 부여하는 제한부 주식단위(RSU)의 여러 유인 보너스를 발표했습니다. 보상위원회는 2025년 6월부터 9월 사이에 총 238,168주를 74명의 신입 직원에게 지급하는 RSU 부여를 승인했습니다.
이 RSU는 동일한 베스팅 일정(취득 일정)을 따르며, 주식의 25%는 1년 후에 취득되고 나머지 주식은 이후 3년 동안 분기별로 취득되며 계속 근무하는 것이 전제 조건입니다. 이러한 부여는 회사의 2019년 개정·재정비된 유인 주식 계획(Amended and Restated 2019 Inducement Equity Plan)에 따라 이루어졌습니다.
BridgeBio Pharma (Nasdaq: BBIO), une société biopharmaceutique spécialisée dans les maladies génétiques, a annoncé plusieurs attributions incitatives d'unités d'actions restreintes (RSU) à de nouveaux employés. Le comité de rémunération a approuvé des attributions de RSU totalisant 238 168 actions réparties entre 74 nouveaux employés entre juin et septembre 2025.
Les RSU suivent un calendrier d'acquisition uniforme : 25 % des actions sont acquises après un an et le reste est acquis trimestriellement au cours des trois années suivantes, sous réserve de la poursuite de l'emploi. Ces attributions ont été réalisées dans le cadre du plan d'actions d'incitation modifié et refondu de 2019 de la Société.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen mit Fokus auf genetische Erkrankungen, hat mehrere Incentive-Zuteilungen in Form von Restricted Stock Units (RSUs) an neue Mitarbeiter angekündigt. Das Vergütungskomitee genehmigte RSU-Zuteilungen in Höhe von insgesamt 238.168 Aktien für 74 neue Mitarbeiter im Zeitraum von Juni bis September 2025.
Die RSUs unterliegen einem einheitlichen Vestingplan: 25 % der Aktien vesten nach einem Jahr, die übrigen Anteile vesten vierteljährlich über die folgenden drei Jahre, vorbehaltlich einer fortdauernden Beschäftigung. Diese Zuteilungen erfolgten im Rahmen des überarbeiteten und neu gefassten Inducement Equity Plan 2019 des Unternehmens.
- None.
- None.
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“RSUs”) to new employees under the Company’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”). The committee approved: (i) on September 5, 2025, RSU grants covering an aggregate of 33,684 shares of the Company’s common stock to 13 new employees; (ii) on August 4, 2025, RSU grants covering an aggregate of 32,145 shares of the Company’s common stock to 16 new employees; and (iii) on July 14, 2025, RSU grants covering an aggregate of 73,991 shares of the Company’s common stock to 20 new employees. One-fourth of the shares underlying these RSUs will vest on August 16, 2026, with the remaining shares vesting in equal quarterly installments over the following three years, subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date. Separately, on June 6, 2025, the committee approved RSU grants covering an aggregate of 98,348 shares of the Company’s common stock to 25 new employees, with one-fourth of the shares vesting on May 16, 2026, and the balance vesting in equal quarterly installments over the following three years, also subject to continued employment with BridgeBio or its subsidiaries on each applicable vesting date.
All of the above-described awards were made under the Plan.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio
FAQ
How many shares were granted in BridgeBio's (BBIO) latest RSU inducement grants?
What is the vesting schedule for BridgeBio's (BBIO) 2025 RSU inducement grants?
How many new employees received RSU grants from BridgeBio (BBIO) in September 2025?
Under which plan were BridgeBio's (BBIO) 2025 RSU grants issued?
